Regeneus is Solidifying Out-Licensing Partnering and Looking to Commence a Japanese Phase II Trial

Mr. John Martin, CEO of the Australian regenerative medicine venture company, Regeneus, relayed his plan to Japan Chemical Daily to locate an out-license partner for the firm’s Knee Osteoarthritis (OA) cellular therapy. Progenza is garnering interest from a number of companies on the back of Regeneus’ Australian Phase I data, which showed possible disease modifying properties. AGC Asahi Glass already has exclusive manufacturing rights for Progenza in Japan.

Read the full interview with Japan Chemical Daily here.